Treatment Sequencing Approaches for Patients With HER2+ mBC

Joseph Gligorov, MD, recommends using tucatinib in combination with trastuzumab and capecitabine as a preferred strategy after trastuzumab deruxtecan, favoring it over another antibody-drug conjugate (ADC) due to limited data on the latter's effectiveness.

Related Keywords

, Real World Evidence , Sequencing Approaches , Patients With , Breast Cancer , Metastatic Breast Cancer , Her2 Metastatic Breast Cancer , Her2 Positive Breast Cancer , Advanced Her2 Positive , Drug Approvals , Thp , T Dx1 , Therapy Considerations , Stable Brain Metastases , Active Brain Metastases , Her2climb 05 ,